ArticleOncogenesis2016
Multi-omics landscapes of colorectal cancer subtypes discriminated by an individualized prognostic signature for 5-fluorouracil-based chemotherapy.
Article in Oncogenesis, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- Serum metabolomics to identify molecular subtypes and predict XELOX efficacy in colorectal cancer.Scientific reports · 2025Article
- A new paradigm in postoperative colorectal cancer surveillance: integrating advanced imaging and multi-omics.Frontiers in physiology · 2025Review
- Article
- Discovery and validation of a 10-gene predictive signature for response to adjuvant chemotherapy in stage II and III colon cancer.Cell reports. Medicine · 2024Article
- Proteomic Profiling and Biomarker Discovery in Colorectal Liver Metastases.International journal of molecular sciences · 2022Review
- Multi-omics reveals microbiome, host gene expression, and immune landscape in gastric carcinogenesis.iScience · 2022Article
- A new natural killer cell-specific gene signature predicting recurrence in colorectal cancer patients.Frontiers in immunology · 2022Article
- DeepProg: an ensemble of deep-learning and machine-learning models for prognosis prediction using multi-omics data.Genome medicine · 2021Article
- Regulation of signal transduction pathways in colorectal cancer: implications for therapeutic resistance.PeerJ · 2021Article
- Predicting the effect of 5-fluorouracil-based adjuvant chemotherapy on colorectal cancer recurrence: A model using gene expression profiles.Cancer medicine · 2020Article
- Characterization of a p53/miR-34a/CSF1R/STAT3 Feedback Loop in Colorectal Cancer.Cellular and molecular gastroenterology and hepatology · 2020Article
- Clinical Role of Epigenetics and Network Analysis in Eye Diseases: A Translational Science Review.Journal of ophthalmology · 2019Review
- Individualized predictive signatures for 5-fluorouracil-based chemotherapy in right- and left-sided colon cancer.Cancer science · 2018Article
- MiR-106a-5p promotes 5-FU resistance and the metastasis of colorectal cancer by targeting TGFβR2.International journal of clinical and experimental pathology · 2018Article
- Discriminating cancer-related and cancer-unrelated chemoradiation-response genes for locally advanced rectal cancers.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Until recently, few prognostic signatures for colorectal cancer (CRC) patients receiving 5-fluorouracil (5-FU)-based chemotherapy could be used in clinical practice. Here, using transcriptional profiles for a panel of cancer cell lines and three cohorts of CRC patients, we developed a prognostic signature based on within-sample relative expression orderings (REOs) of six gene pairs for stage II-III CRC patients receiving 5-FU-based chemotherapy. This REO-based signature had the unique advantage of being insensitive to experimental batch effects and free of the impractical data normalization requirement. After stratifying 184 CRC samples with multi-omics data from The Cancer Genome Atlas into two prognostic groups using the REO-based signature, we further revealed that patients with high recurrence risk were characterized by frequent gene copy number aberrations reducing 5-FU efficacy and DNA methylation aberrations inducing distinct transcriptional alternations to confer 5-FU resistance. In contrast, patients with low recurrence risk exhibited deficient mismatch repair and carried frequent gene mutations suppressing cell adhesion. These results reveal the multi-omics landscapes determining prognoses of stage II-III CRC patients receiving 5-FU-based chemotherapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.